AlphaGrep UK’s Guardant Health GH Stock Holding History

AlphaGrep UK’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Sell	2,116 -684	-24%	-$74.4K	0.09%	440
2026 Q1	$259K	Buy	2,800 +693	+33%	+$69.6K	0.07%	584
2025 Q4	$215K	Buy	+2,107	New	+$188K	0.07%	598

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AlphaGrep UK's GH Position: Q2 2026 in Review

AlphaGrep UK reduced its Guardant Health (GH) stake by 24% in Q2 2026, selling an estimated $74.4K and leaving 2,116 shares worth $317K. The position accounts for 0.09% of the portfolio, ranked #440.

AlphaGrep UK first reported a position in GH in Q4 2025 and has held it in 3 quarters since. 550 funds tracked by Wall St. Rank hold GH as of Q2 2026.

AlphaGrep UK held 2,116 shares of Guardant Health worth $317K as of Q2 2026.
AlphaGrep UK sold 684 Guardant Health shares in Q2 2026, an estimated $74.4K.
Guardant Health made up 0.09% of AlphaGrep UK's portfolio in Q2 2026, its #440 holding.
AlphaGrep UK first reported a position in Guardant Health in Q4 2025 and has held it in 3 quarters since.
550 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.